COOPER COMPANIES, INC.
Nasdaq: COO·San Ramon, California·CIK 0000711404
- Price
- $61.88
- Base IV
- $42.75
Valuation snapshot
At $61.88, the price sits between our base case ($42.75) and bull case ($70.24).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $42.75
- 69% of the price · range $18.54–$70.24
- Price vs base case
- 45% above
- $61.88 against $42.75
- Base case · our researched forecast, 2026-11-11See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $18.54 to bull $70.24. Values per share.
Price against each value
- Bear case
- $18.54
- Price 234% above
- No growth
- …
- —
- Base case
- $42.75
- Price 45% above
What does Cooper Companies do?
The Cooper Companies provides contact lenses for vision correction and myopia management, alongside medical devices and services for fertility and women's health.
It brought in $4.2B of sales in the 12 months to Jul 2026.
- Industry
- Healthcare
- Based in
- San Ramon, California
- Trades on
- Nasdaq as COO
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Jul 2026, about 13¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 45¢ of every dollar.
- Making what it sells34¢
- Research and development4¢
- Sales, marketing and admin45¢
- Everything else it takes to operate5¢
- Interest and other costs2¢
- Left as profit13¢
- Tax credit came back in+3¢
Who pays Cooper Companies, and for what?
Cooper makes contact lenses and products and services for fertility and women’s health. It earns revenue by selling these products and services through its two businesses, CooperVision and CooperSurgical.
Its customers include eye care practitioners and retailers, hospitals, surgery centers, OB/GYN offices, fertility clinics and, for some services, consumers.
Toric and multifocal contact lenses
33%Contact lenses that correct common vision needs and more complex conditions such as astigmatism and presbyopia.
Sphere and other contact lenses
34%Contact lenses for near- and farsightedness, myopia management and other specialty needs.
Biofinity and Biofinity XR contact lensesImage: CooperVision Office and surgical
20%Women’s health products and services used in medical offices, hospitals and surgery centers, including contraception and cord blood and tissue storage.
Fertility
13%Products and services used in fertility care, including IVF supplies and equipment, donor services, cryostorage and genetic testing.
CooperSurgical culture mediaImage: CooperSurgical
Where its work physically happens, beyond headquarters:
- CooperVision Juana Díaz plant — Juana Díaz, Puerto Rico. This 540,000-square-foot plant produces MyDay and Biofinity contact lenses, making it a major source of CooperVision supply.
- CooperVision Hamble plant — Hamble, United Kingdom. The Hamble contact lens plant forms part of CooperVision’s United Kingdom manufacturing base, which the company identifies as a primary source of its molded lenses.
- CooperVision Budapest plant — Budapest, Hungary. The Budapest facility produces clariti 1 day lenses and is one of CooperVision’s high-volume manufacturing locations.
- CooperVision Scottsville plant — Scottsville, United States. The Scottsville facility manufactures customized Biofinity toric multifocal lenses for North American customers, shortening delivery times for made-to-order products.
- CooperVision Alajuela plant — Alajuela, Costa Rica. This high-volume plant manufactures clariti 1 day silicone hydrogel lenses, adding capacity for CooperVision’s daily disposable products.
How is the business doing?
Sales grew from $2.4B in 2020 to $4.1B in 2025, about 11% a year.
Running the business leaves about 13¢ of each sales dollar as operating profit, about the same as 13¢ in 2020.
After paying for its upkeep and new investment, it had $678M of cash to spare in the 12 months to Jul 2026.
What does management say it's aiming for?
Cooper says its purpose is to help people experience life’s beautiful moments.
“Helping people experience life's beautiful moments”
What management says it is working on now:
Accelerate CooperVision innovation
Cooper is investing in research and development and has accelerated six contact lens product advancements for launch over the next several years.
CooperCompanies Unveils Accelerated CooperVision Innovation StrategyStrengthen CooperVision commercial execution
The company says it is expanding CooperVision’s global sales and marketing organization and pursuing greater market penetration for its products.
CooperCompanies Completes Strategic ReviewImprove operations and customer service
Cooper is working on cost and efficiency improvements and inventory and logistics changes intended to improve customer service.
CooperCompanies Completes Strategic ReviewGrow fertility and women’s health
Management says it remains focused on growing fertility and improving the performance of CooperSurgical.
CooperCompanies Completes Strategic Review
- Fiscal 2026 total revenue, Fiscal 2026
- $4.229 billion to $4.252 billion
- CooperCompanies Announces Third Quarter 2026 Results
- Fiscal 2026 CooperVision revenue, Fiscal 2026
- $2.828 billion to $2.842 billion
- CooperCompanies Announces Third Quarter 2026 Results
- Fiscal 2026 CooperSurgical revenue, Fiscal 2026
- $1.401 billion to $1.410 billion
- CooperCompanies Announces Third Quarter 2026 Results
- Free cash flow, Fiscal 2026 through fiscal 2028
- Exceed $2.2 billion
- CooperCompanies Announces Third Quarter 2026 Results
What's changing right now?
Growth is slowing. In Q3 2026 it sold 1% more than a year earlier. The year before, quarters averaged 6%.
Its operating margin is wider than a year ago: 21¢ per sales dollar, against 17¢.
Since Oct 2026 the share price has risen 3%, from $60.34 to $61.88.
Recently
September 9, 2026
CooperVision quarterly organic sales growth changed to 0.0%
Q3 2026 CooperVision organic growthDecember 4, 2025
Full-year capital expenditure share of sales changed to 8.9%
Fiscal 2025 results
Coming up
Over the next several years
Contact lens product advancements
CooperVision announced six product advancements, including new daily lenses and lens materials, for launch over the next several years.
CooperCompanies Unveils Accelerated CooperVision Innovation StrategyExpected December 2026
Fiscal 2026 fourth-quarter results
The company’s next scheduled reporting event is its fiscal fourth-quarter results, which will provide an update on performance and full-year results.
CooperCompanies Events & Presentations
Our own estimate moved too: the base case went from $27.13 to $42.75 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Competition and pricing pressure
The company competes with large medical device and contact lens makers. New products, lower prices or changes in customer purchasing and insurance coverage could reduce sales or the prices Cooper can charge.
From the company's own filingsWould hit how fast sales growCooperCompanies 2025 Form 10-K
Regulatory approvals and compliance
Medical devices and tests face detailed rules in the United States and other countries. Delayed approvals or failure to meet requirements could delay launches, restrict sales or require costly changes.
From the company's own filingsWould hit how fast sales growCooperCompanies 2025 Form 10-K
Manufacturing and supplier interruptions
Some lens materials and other components come from sole or limited suppliers, and certain products are made at a single approved site. A disruption could limit product availability, delay deliveries and reduce sales.
From the company's own filingsWould hit how fast sales growCooperCompanies 2025 Form 10-K
ERP system implementation
Cooper is implementing new business software systems. A difficult rollout could disrupt orders, deliveries, accounting or reporting, and the company says it cannot guarantee implementation will go smoothly.
From the company's own filingsWould hit how much of each sale it keepsCooperCompanies 2025 Form 10-K
Economic and international pressures
Inflation, currency movements, tariffs and weaker customer finances could raise costs or reduce purchases. About half of sales come from outside the United States, exposing the company to conditions and rules across many countries.
From the company's own filingsWould hit how fast sales growCooperCompanies 2025 Form 10-K
Cybersecurity incidents
An attack on Cooper or a service provider could interrupt operations or expose health, customer or company data, leading to financial, legal and reputational harm.
From the company's own filingsWould hit how much of each sale it keepsCooperCompanies 2025 Form 10-K
US channel inventory reduction continues into Q4.
From our researchWould hit how fast sales growQ3 2026 results
Cooper is expanding its sales and marketing organization.
From our researchWould hit how much of each sale it keepsStrategic review conclusions
Is it a good business?
From 2016 to 2025 it earned between 4% and 9% on the capital invested in it, a median of 6%. Its cost of capital in the latest valuation is 7.9%; returns were above it in 2 of the 10 years.
From 2016 to 2025 it earned between 4% and 42% on its shareholders' equity, a median of 6%.
Over 10 years its operating margin ranged from 13¢ to 21¢ per sales dollar, a median of 17¢. Gross margin ran from 60¢ to 67¢.
Cost of capital 7.9%
It bought back shares: the count fell 3.3% in a year, so each remaining share owns a slightly bigger slice.
It owes $2.4B more than it holds in cash, about 4.4 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $61.88. Our put its value between $18.54 and $70.24, with $42.75 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $18.54
The recent sales slowdown lasts, and Cooper earns less from each sale while spending heavily to keep its factories and products competitive.
Base case, $42.75
Cooper gradually recovers from the recent sales slowdown, and better factory use helps it keep more cash as growth settles.
Bull case, $70.24
The recent slowdown proves temporary, new lenses restore faster sales growth, and Cooper turns its recovering profits into substantially more cash.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 45%
For Cooper Companies to be worth today's $61.88, sales would need to grow about 11.3% a year. We assume 4.3%. Over the last 5 years, sales grew 8.3% a year.
Or, if sales grow 4.3% as we assume, the price works with a profit margin of 29.6% (we assume 22.0%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 11.3% a year?
Try your own numbersWe're moderately sure of this range: it scores 53 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $42.75 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average4.3%
- Operating margin22.0%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$42.75 -30.9%

